Edition:
United Kingdom

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

32.88USD
21 Feb 2018
Change (% chg)

$-0.29 (-0.87%)
Prev Close
$33.17
Open
$33.50
Day's High
$34.00
Day's Low
$32.77
Volume
88,260
Avg. Vol
142,803
52-wk High
$41.24
52-wk Low
$16.71

Latest Key Developments (Source: Significant Developments)

Broadfin Capital Reports 5 Percent Passive Stake In La Jolla Pharmaceutical - SEC Filing‍​
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - La Jolla Pharmaceutical Co ::BROADFIN CAPITAL LLC REPORTS 5 PERCENT PASSIVE STAKE IN LA JOLLA PHARMACEUTICAL CO AS OF JAN 9 - SEC FILING‍​.  Full Article

La Jolla Pharmaceutical Says Cash Resources Are Expected To Fund Co Into Second Half Of 2018
Friday, 29 Dec 2017 

Dec 29 (Reuters) - La Jolla Pharmaceutical Co ::LA JOLLA PHARMACEUTICAL SAYS CASH RESOURCES ARE EXPECTED TO FUND CO INTO SECOND HALF OF 2018 - SEC FILING.  Full Article

La Jolla Says FDA Approved Drug To Treat Critically Low Blood Pressure
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - La Jolla Pharmaceutical Co ::U.S. FOOD AND DRUG ADMINISTRATION SAYS APPROVED GIAPREZA (ANGIOTENSIN II) TO TREAT DANGEROUSLY LOW BLOOD PRESSURE.U.S. FDA SAYS GRANTED THE APPROVAL OF GIAPREZA TO LA JOLLA PHARMACEUTICAL COMPANY.U.S. FDA - APPROVES GIAPREZA (ANGIOTENSIN II) INJECTION FOR INTRAVENOUS INFUSION TO INCREASE BLOOD PRESSURE IN ADULTS WITH SEPTIC/OTHER DISTRIBUTIVE SHOCK.  Full Article

La Jolla Pharmaceutical Initiates Multicenter, Randomized, Phase 2 Clinical Study Of LJPC‑401
Monday, 18 Dec 2017 

Dec 18 (Reuters) - La Jolla Pharmaceutical Co ::INITIATION OF MULTICENTER, RANDOMIZED, PHASE 2 CLINICAL STUDY OF LJPC‑401 IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS.  Full Article

La Jolla Pharma files for mixed shelf of up to $150 mln ‍​
Friday, 27 Oct 2017 

Oct 27 (Reuters) - La Jolla Pharmaceutical Co :Files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

La Jolla reports Q3 loss $1.19/shr
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - La Jolla Pharmaceutical Co :La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2017 and recent corporate progress.Q3 loss per share $1.19.Q3 earnings per share view $-1.24 -- Thomson Reuters I/B/E/S.La Jolla Pharmaceutical-‍as of Sept 30, 2017, co had $120.8 million in cash,cash equivalents, versus $65.7 million of cash and cash equivalents at Dec 31, 2016​.  Full Article

Prudential Financial reports 10.1 pct passive stake ​in La Jolla Pharmaceutical
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - La Jolla Pharmaceutical Co ::Prudential Financial Inc reports 10.1 percent passive stake ​in La Jolla Pharmaceutical Co as of Sept 30 - sec filing ‍.  Full Article

La Jolla Pharmaceutical Company announces financial results for the three and six months ended June 30, 2016
Monday, 8 Aug 2016 

La Jolla Pharmaceutical Co : La Jolla Pharmaceutical Company announces financial results for the three and six months ended June 30, 2016 . Quarterly loss per share $0.90 .Q2 earnings per share view $-0.99 -- Thomson Reuters I/B/E/S.  Full Article

La jolla Pharmaceutical Co reports Q1 loss per share of $0.96
Friday, 6 May 2016 

La Jolla Pharmaceutical Co : La jolla pharmaceutical company announces first quarter 2016 financial results and recent corporate progress . Q1 loss per share $0.96 . Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S .Qtrly total revenue $234,000.  Full Article

BRIEF-La Jolla Pharmaceutical Announces Treatment Of First Patient In Giapreza Pediatric Study

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES THE TREATMENT OF FIRST PATIENT IN GIAPREZA (ANGIOTENSIN II) PEDIATRIC STUDY Source text for Eikon: Further company coverage: